ClinicalTrials.gg
WithdrawnNCT02624544Updated Aug 5, 2022

Proton Pump Inhibitors Use in Patients With Psoriasis

A Phase 4 interventional study of esomeprazole and desonide in Psoriasis, sponsored by EMS. Withdrawn. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by EMS · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

Read the detailed description

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

The study will assess the evolution of skin lesions in psoriasis patients using PPIs

02

Conditions studied

  • Psoriasis

Browse trials for

03

In context

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Lead sponsor

EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnostic of Psoriasis

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group A

    Proton Pump Inhibitor esomeprazole 40 mg twice a day

    Drug: esomeprazole

  • Active comparator
    Group B

    desonide

    Drug: desonide

Interventions

  • esomex 40 mg twice daily

    Also known as: esomex

  • topical corticosteroid desonid 0,1% b.i.d

    Also known as: corticosteroid

06

What researchers measure

Primary outcomes

  1. Efficacy - Change from baseline in skin lesions at 5 months

    Number of Participants With Treatment-Related Clinical Improvement of lesions Change From Baseline in skin lesions at 5 months

    Time frame: Baseline - 5 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rahman M, Alam K, Ahmad MZ, Gupta G, Afzal M, Akhter S, Kazmi I, Jyoti, Ahmad FJ, Anwar F. Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):287-302. doi: 10.2174/187153012802002901. PubMed 22463723 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2016 (actual). Primary completion is estimated for Jan 2016, 0 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2015
First posted
Dec 8, 2015
StartActual
Jan 2016
Primary completionEst.
Jan 2016
CompletionEst.
Dec 2016
Last update
Aug 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02624544
Lead sponsor
EMS
Responsible party
Sponsor
First posted
Dec 8, 2015
Start date
Jan 2016
Primary completion
Jan 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Aug 5, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion